RVL Pharmaceuticals PLC reports results for the quarter ended in June - Earnings Summary

RVL Pharmaceuticals

14/08/2023 14:31

* RVL Pharmaceuticals PLC  RVLP.OQ  reported a quarterly
adjusted
loss of 24 cents​​ per share for the quarter ended in June. The
mean expectation of five analysts for the quarter was for a loss
of 11 cents per share.
    * Revenue fell 2.2% to $8.26 million from a year ago;
analysts
expected $10.62 million. 
    * RVL Pharmaceuticals PLC's reported EPS for the quarter was
a
loss of 24 cents​.
    * The mean earnings estimate of analysts had fallen by
about 0.5%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * RVL Pharmaceuticals PLC shares had fallen by 18.2% this
quarter and lost 59.1% so far this year.
    * The company reported a quarterly loss of $23.89 million.
    * Wall Street's median 12-month price target for RVL
Pharmaceuticals PLC is $3.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 14 at 01:31 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.11          -0.24          Missed
 Mar. 31 2023      -0.12          -0.12          Met
 Dec. 31 2022      -0.16          -0.18          Missed
 Sep. 30 2022      -0.16          -0.16          Met